Skip to content

Effect of Benzydamine Hydrochloride Mouthrinse on Plaque Accumulation in Periodontally Healthy Female Subjects

Effect of Benzydamine Hydrochloride During Short-term Restricted Oral Hygiene: a Randomized, Placebo-controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07565766
Acronym
BHCl-PLAQUE
Enrollment
50
Registered
2026-05-04
Start date
2013-02-01
Completion date
2013-05-01
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Health, Plaque Induced Gingival Disease

Keywords

Benzydamine Hydrochloride, Randomized Controlled Trial, Dental plaque, Oral hygiene, Anti-inflammatory Agent

Brief summary

The goal of this clinical trial is to evaluate the effect of a mouthrinse containing an active ingredient benzydamine hydrochloride in the absence of daily oral hygiene. The study includes periodontally healthy female subjects and experimental phase will last for three days. Plaque accumulation is the primary evaluated outcome, measured by a particular periodontal index called Plaque Control Record (PCR). Gingival inflammation (bleeding) is the secondary evaluated outcome, measured by a particular periodontal index called Bleeding on Probing (BoP). Researchers will compare benzyadamine hydrochloride mouthrinse to a placebo (a look-alike substance that contains no active ingredient) mouthwash to see whether benzydamine hydrochloride use results in greater plaque accumulation.

Detailed description

This study is designed as a randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the effects of a benzydamine hydrochloride-containing mouthrinse on supragingival plaque accumulation and gingival inflammatory response under conditions of restricted mechanical oral hygiene. The experimental model is based on a short-term plaque regrowth protocol, enabling controlled assessment of the chemical effects of the investigational product in the absence of confounding mechanical plaque removal. A total of 50 periodontally healthy female participants will be enrolled and randomly assigned to either the test group (benzydamine hydrochloride mouthrinse) or the control group (placebo mouthrinse). Randomization will be performed using a predefined allocation sequence to ensure balanced group distribution. Both participants and investigators will be blinded to group assignment, with the test and placebo formulations matched in color, taste, and packaging to maintain allocation concealment. Prior to the experimental phase, all participants will receive professional dental prophylaxis to establish a standardized baseline with minimal plaque accumulation and absence of gingival inflammation. Following this, subjects will be instructed to refrain from all mechanical oral hygiene procedures, including toothbrushing and interdental cleaning, for the duration of the 3-day experimental period. During the experimental phase, participants will use the assigned mouthrinse twice daily, rinsing with 15 mL of solution for a standardized duration according to detailed written instructions. The investigational product contains benzydamine hydrochloride, a locally acting non-steroidal anti-inflammatory agent with analgesic and anti-inflammatory properties, which may influence gingival tissue response and potentially affect plaque accumulation dynamics. The placebo formulation is devoid of active pharmacological ingredients but is otherwise identical in formulation characteristics to ensure effective blinding. Clinical assessments will be conducted at baseline and at the end of the 3-day experimental period. Plaque accumulation will be assessed using the Plaque Control Record (PCR), which quantifies the presence of plaque on six tooth surfaces and expresses the findings as a percentage of plaque-positive sites. Gingival inflammation will be evaluated as a secondary outcome using Bleeding on Probing (BoP), recorded dichotomously following periodontal probing. All clinical measurements will be performed by a previously calibrated examiner using standardized instruments and probing force to ensure consistency and reproducibility of recorded data. This study design allows for the isolation of the chemical effects of benzydamine hydrochloride by eliminating mechanical plaque control, thereby providing insight into its influence on early plaque formation and gingival inflammatory response compared to placebo. The short duration of the experimental phase ensures participant safety while allowing detection of early biological changes in plaque accumulation and gingival health.

Interventions

Participants assigned to the intervention arm will use a mouthrinse containing benzydamine hydrochloride twice daily. A volume of 15 mL will be used per rinse, following a standardized rinsing duration in accordance with the manufacturer's instructions. During the 3-day experimental period, participants will refrain from all mechanical oral hygiene measures to allow assessment of the chemical effects of the mouthrinse on plaque accumulation and gingival inflammation.

Participants assigned to the placebo arm will use a mouthrinse without active pharmacological ingredients, formulated to match the test product in color, taste, and packaging to ensure blinding. The mouthrinse will be used twice daily in a volume of 15 mL, following a standardized rinsing duration in accordance with the manufacturer's instructions. Mechanical oral hygiene measures will be suspended throughout the 3-day experimental period.

Sponsors

University of Zagreb
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* dentate subjects with at least 24 healthy teeth * no history of periodontal disease, confirmed by a clinically healthy periodontium, defined as probing pocket depth (PPD) ≤ 3 mm and no interdental clinical attachment loss

Exclusion criteria

* pregnant or lactating females * using hormonal contraceptives * reporting systemic diseases or pharmacological treatment that could affect gingival inflammation * use of antibiotics within 6 months before the study

Design outcomes

Primary

MeasureTime frameDescription
3-day plaque accumulation assessed by Plaque Control Record (PCR)Baseline (Day 0) and Day 3Plaque accumulation will be evaluated using the Plaque Control Record (PCR), which assesses the presence or absence of supragingival plaque on six surfaces of each tooth. The results will be expressed as the percentage of plaque-positive surfaces relative to the total number of examined surfaces, providing a quantitative measure of plaque regrowth under conditions of suspended mechanical oral hygiene.

Secondary

MeasureTime frameDescription
3-day gingival inflammation assessed by Bleeding on Probing (BoP)Baseline (Day 0) and Day 3Gingival inflammation will be assessed using Bleeding on Probing (BoP), recorded dichotomously (presence/absence of bleeding) following gentle probing of the gingival sulcus at standardized sites. The outcome will be expressed as the percentage of bleeding-positive sites, reflecting the degree of gingival inflammatory response.

Countries

Croatia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026